Alfredo Lozada/LinkedIn
Sep 11, 2026, 09:51
Alfredo Lozada: Pelacarsen Lowers Lp(a), But Does It Lower CV Risk?
Alfredo Lozada, Founder of Clinica del Colesterol at Cholesterol Clinic, shared a post on LinkedIn:
“Futility of Pelacarsen in the Lipoprotein(a) HORIZON !!
8,323 people with Lpa and CV disease. Designed to prove a reduction CV events .
Pelacarsen lowered Lp(a), but the study did not reduce CV Events.
- Important information, has not been presented. For patients, the message is clear: this announcement does not change the genetics & management of Lp(a). For clinicians, keep driving LDL-C to target, blood pressure, and managing risk factors.
- Maybe patients need to start reducing Lpa much earlier to get benefit. The Diminishing Returns graph & theory attached, shows that earlier Tx is needed !! As with inflammation you need to fight the fire, not the ashes !!
We wait the data release from other ongoing outcome trials to understand the next steps in CV prevention. What will you do at home?”
Stay updated with Hemostasis Today.
-
Oct 23, 2026, 16:05Platelet Secretion Defects and Their Role in the Diagnosis of Bleeding Disorders
-
Oct 23, 2026, 16:00Hemophilia Alliance team in New Orleans at the ATHN Data Summit
-
Oct 23, 2026, 15:49Brian Sapp: Why Exact Calf Vein Naming Is Critical for DVT Diagnosis?
-
Oct 23, 2026, 15:33Smitirupa Mishra: A Systematic Approach to Bone Marrow Examination
-
Oct 23, 2026, 15:29José Antonio García Erce: Preoperative Anemia Emerges as a Modifiable Surgical Risk in New POWER Study
-
Oct 23, 2026, 15:13Reza Shojaei: Manufactured Red Blood Cells vs Blood Donation
-
Oct 23, 2026, 14:29Jean Jacques Kiladjian: International Scientific Exchange at IHCAMS in Tianjin
-
Oct 23, 2026, 14:11Aravind Palraj: The Prolonged aPTT Puzzle in SLE
-
Oct 23, 2026, 13:56Chokri Ben Lamine: The Evolving Treatment Landscape of Persistent and Chronic ITP